(764) Left Ventricular Assist Device Implantation Outcomes: Single-Center Experience in a Latin American Advanced Heart Failure Reference Program

PurposeLeft ventricular assist device (LVAD) improves 5-year survival and quality of life in advanced heart failure patients. However, feasibility long-term outcomes developing countries are unknown. We evaluate the actuarial adverse events rate a cohort patients implanted largest MCS program Colombia, South AmericaMethodsAll adult who received durable LVAD at Fundación Cardiovascular de Colombia (FCV), Floridablanca, from 2014 to 2022 were included. Actuarial survival, early late neurologic dysfunction, related infection pump thrombosis calculated.ResultsTwenty-seven included (Median age: 52 years; 54% females). The most frequent etiology HF was ischemic cardiomyopathy (24%), followed by hypertensive valvular diseases (16% 12%, respectively). Eight had HeartMate II implanted, 18 Heartmate III, only one HVAD implanted. median duration support 35 months (1.3 - 95 months); 6-month, 1-, 2-, 3- 4-year rates 88%, 84%, 78%, 65%, respectively. Early (less than three months) per 100 patient-month were: 0 0.82;, stroke 2.65 0.62; 0.31 (All occurred HM II) After eight years 5 have been transplanted, 7 died 15 active on supportConclusionThe use for with end-stage country is associated longterm profiles that comparable reported large Registries. Left America All calculated. Twenty-seven